APA (7th ed.) Citation

Ferrante, M., Feagan, B. G., Panés, J., Baert, F., Louis, E., Dewit, O., . . . D'Haens, G. R. (2021). Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. Journal of Crohn's & Colitis, 15(12), 2001. https://doi.org/10.1093/ecco-jcc/jjab093

Chicago Style (17th ed.) Citation

Ferrante, Marc, et al. "Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study." Journal of Crohn's & Colitis 15, no. 12 (2021): 2001. https://doi.org/10.1093/ecco-jcc/jjab093.

MLA (9th ed.) Citation

Ferrante, Marc, et al. "Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study." Journal of Crohn's & Colitis, vol. 15, no. 12, 2021, p. 2001, https://doi.org/10.1093/ecco-jcc/jjab093.